News
Discovery of MCM2-7 complex is new therapeutic target for neuroendocrine prostate cancer
June 2021
Exiting new study from our lab identifies MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer. Congratulations En-chi and team!
June 2021
Exciting news: Dr. Busola Alabi joins Stoyanova lab!
Welcome to the team Busola!
April 2021
Laura received Justice, Diversity, Equity & Inclusion Seed Grants
"Developing Stanford-Clark Atlanta University Research Program"
Project Lead: Shiqin Liu, Team Members: Merve Aslan, Tanya Stoyanova
Congratulations Laura and team!
https://med.stanford.edu/radiology/news/2021/justice-diversity-equity-inclusion-seed-grants.html
April 2021
Exciting news: Dr. Manoj Kumar awarded Sanjiv Sam Gambhir – PHILIPS Fellowship in Precision Medicine (PHIND) for "Development of Trop2 Targeted PET-imaging Probe and Therapy for Cancer." He is a Postdoctoral Research Fellow in Stoyanova Lab.
Congratulations Manoj!
https://canarycenter.stanford.edu/news-events/canary-news/202-philips-fellowship.html
New review article on the role of Trop2 in prostate cancer
February 2021
Stoyanova Lab publishes a review article discussing the role of Trop2 in prostate cancer. Congratulations Michelle!
Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay
April 2021
Exiting new study from our lab suggest that CASP8 may serve as a biomarker for high-risk prostate cancer and potentially renal cancer. Congratulations Laura and team.
https://www.nature.com/articles/s41598-021-87155-5
Dr. Demirci and Dr. Stoyanova receive Spectrum MedTech Pilot Grant
January 2021
Dr. Demirci and Dr. Stoyanova receive Spectrum MedTech Pilot Grant
“An automated disposable tool for liquid biopsy-based detection of exosomal biomarkers for early cancer detection”
Developing new imaging approach for methionine aminopeptidase II for prostate cancer risk stratification
February 2021
Exciting new results from our lab collaborative work reveal a new imaging approach for risk stratification of prostate cancer.
Discovery of ferroptosis inducers as a new therapeutic strategy for advanced prostate cancer
January 2021
New study from our lab demonstrates that ferroptosis inducers reprsent a new therapeutic approach for advanced prostate cancer.
https://cancerres.aacrjournals.org/content/81/6/1583.long
Identification of a new serum biomarker for clinically significant prostate cancer
December 2020
Exciting new results from our lab collaborative work reveal PTN as a new serum biomarker of pro-metastatic prostate cancer. Congratulations Shiqin and all collaborators!
Identification of a new important regulator of prostate cancer growth and metastasis
December 2020
New study from our lab demonstrates plectin is an important regulator of prostate cancer growth and metastatic colonization. Congratulations Mark, Meghan and team.
https://www.nature.com/articles/s41388-020-01557-9
November 2020
Tanya Stoyanova receives 2020 Society of Basic Urologic Research Young Investigator Award from the Society of Basic Urologic Research
Congratulations Tanya!
November 2020
En-chi Hsu receives Travel Award from the Society of Basic Urologic Research
Congratulations En-chi!
November 2020
Merve Aslan receives Travel Award from the Society of Basic Urologic Research
Congratulations Merve!
October 2020
Exciting news: Dr. Manoj Kumar joins Stoyanova lab!
Welcome to the team Manoj!
https://profiles.stanford.edu/manoj-kumar
July 2020
Stoyanova Lab Receives NCI R01 Grant
Stoyanova lab is awarded NIH/NCI R01 funding for the proposal entitled:
"Elucidating the Role of UCHL1 in Aggressive Prostate Cancer"
The goal of the project is to identify new molecular mechanisms underlying the development of highly aggressive neuroendocrine prostate cancer and develop new therapies for the matasatic disease.
Congratulations!
May 2020
Dr. Tanya Stoyanova Receives NCI R01/R37 MERIT Award
Dr. Stoyanova is awarded the NIH/NCI R01/R37 MERIT Award for her proposal entitled:
"Elucidating the Role of Trop2 in Prostate Cancer"
The goal of the project is to test the role of a cell surface receptor activation in aggressive prostate cancer. The study will define novel mechanisms that contribute to the development of advanced prostate cancer and test new therapies for the advanced disease.
Congratulations Dr. Stoyanova!
May 2020
Michelle Shen Receives VPUE Stanford Undergraduate Research Major Grant for her project entitled:
"Defining Novel Therapeutics for Advanced Neuroendocrine Prostate Cancer"
The goal if the project is to define new therapies for highly aggressive subtype of prostate cancer.
Congratulations Michelle!
Identification of a new driver and therapeutic target for a highly aggressive subtype of prostate cancer
January 28, 2020
Exciting new results from our lab identifying a new driver and therapeutic target for highly aggressive metastatic prostate cancer with neuroendocrine features are published in PNAS. Congratulations En-Chi!
January 2020
Jordan Lee, undergraduate student at Stanford, joins the lab. Welcome Jordan!
New review article on prostate cancer therapies published
August 28, 2019
Stoyanova Lab publishes a review article discussing second-generation anti-androgen therapies for prostate cancer. Congratulations Meghan!
June 2019
Michelle Shen, undergraduate student at Stanford, joins the lab. Welcome Michelle!
Stoyanova lab launches it's first manuscript
April 26, 2019
Excellent work by Stoyanova Lab, showing that loss of Notch1 activity inhibits prostate cancer growth and metastasis and sensitizes prostate cancer cells to anti-androgen therapies.
March 2019
Dr. Ali Ghoochani, Postdoctoral Fellow in Stoyanova Lab awarded Department of Defense, Prostate Cancer Research Program, Early Investigator Award for his project title:
"Ferroptosis Induction is a Novel Therapeutic Strategy for Advanced Prostate Cancer"
The overall goal of the proposed research is to develop novel therapeutic strategies that improve outcomes for men with lethal prostate cancer. In the proposed research, we aim to assess the therapeutic potential of ferroptosis induction (Iron-dependent cell death) by erastin treatment in advanced prostate cancer. We will also evaluate the therapeutic potential of ferroptosis induction in combination with FDA approved second-generation anti-androgens Enzalutamide and Abiraterone. Additionally, we will investigate the molecular mechanisms through which ferroptosis induction affects prostate cancer. Completion of the proposed research will lead to the development of novel therapeutic strategies for advanced prostate cancer and thus significantly reduce mortalities associated with lethal prostate cancer.
March, 2019
Welcome Dr. Shiqin Liu
The Stoyanova lab is excited to announce the addition of Postdoctoral Fellow, Dr. Shiqin Liu, to the team.
Welcome!
October, 2018
Stoyanova Lab awarded NCI Small Grants Program for Cancer Research award for the project titled:
"Elucidating novel mechanisms underlying prostate cancer development"
The major goals of the proposed project are to define novel mechanisms through which Trop2 contributes to the development of advanced prostate cancer. The study will also develop new the therapeutic strategies to target Trop2 activity. Completion of the proposed research will give us insights into new mechanisms underlying the development of aggressive prostate cancer and open novel avenues for therapeutic intervention.
Congratulations!
2018 Canary Challenge Fundraiser
Thank you to everyone who came out to support the important cause of cancer early detection. Together, the Canary Center Team raised over $30,000 this year at the 2018 Canary Challenge. We are overjoyed at this achievement and are grateful for everyone's committment.
Thank you and Congratulations to all participants and volunteers!
Please visit www.canarychallenge.com to obtain more information.
May, 2018
Stoyanova Lab awarded Department of Defense, Prostate Cancer Research Program, Idea Development Award for project title:
"Trop2 as a novel driver and therapeutic target for castration-resistant prostate cancer"
The proposed research aims to define new drives and therapeutic targets for advanced prostate cancer. We have recently demonstrated that cell surface protein, Trop2, represents a new promising therapeutic target for advanced prostate cancer. The proposed project will evaluate novel strategies to target Trop2 in aggressive prostate cancer. Identifying new therapeutic strategies and pathways and mechanisms that contribute to the development of aggressive prostate cancer will significantly advance the field of prostate cancer research.
Congratulations!
May, 2018
Dr. Meghan Rice, PhD, Postdoctoral Fellow in Stoyanova Lab awarded Department of Defense, Prostate Cancer Research Program, Early Investigator Research Award for her project title:
"Defining the Role and Therapeutic Potential of Notch Signaling in Aggressive Prostate Cancer"
The overall goal of this proposal is to understand the mechanisms causing aggressive prostate cancer. The proposed project will investigate the role of Notch signaling pathway in prostate cancer to understand the mechanism through which Notch can drive the aggressive disease and determine the requirement of Notch for tumor maintenance. Additionally, we will test new treatment strategies involving two types of Notch inhibitors alone, and in combination with current standard of care treatments for castration resistant disease. This study will facilitate our understanding of fundamental molecular mechanisms underlying the development of aggressive prostate cancer and direct novel strategies regarding new combination therapies for the advanced disease.
Congratulations Dr. Rice!
May 2018
Austin You Su, Undergraduate Student in the Stoyanova Lab receives Undergraduate Advising Research (UAR) award
Austin You Su Awarded summer research funding for the design and planning of a series of experiments to assess the role of Aurora A Kinase in prostate cancer progression, under the guidance of his mentor Professor Tanya Stoyanova.
The Office of Undergraduate Advising and Research (UAR) helps students realize the full intellectual richness of undergraduate life at Stanford. Undergraduate Advising and Research (UAR) Student Grants support rigorous, independent projects in all disciplines. Research, arts, and senior synthesis projects in any field (including engineering, fine arts, humanities, natural sciences, and social sciences) can make use of this funding.
Austin also received a perfect score in the MCAT exam.
The Medical College Admission Test® (MCAT®), developed and administered by the AAMC, is a standardized, multiple-choice examination created to help medical school admissions offices assess your problem solving, critical thinking, and knowledge of natural, behavioral, and social science concepts and principles prerequisite to the study of medicine.
Congratulations Austin!
The Canary Center at Stanford and Cancer Research UK Cambridge Centre collaborate to fund innovative research to help diagnose cancer earlier. The awards were announced at Cambridge’s third annual early detection symposium on January 15.
January 2018
Congratulations Dr. Stoyanova and Dr. Gnanapragasam!
August 2017
Mark Buckup, Undergraduate Student in the Stoyanova Lab receives the Verily Young Scientist Award
Canary Center summer internship student Mark Buckup wins the Verily Young Scientist Award for his poster titled: "Elucidating the Role of Legumain in Prostate Cancer".
Congratulations Mark!
Photo on left features Mark Buckup, Student Intern and Dr. Stephanie van de Ven, Canary Center Deputy Director Programs
June 2017
Dr. Meghan Rice receives best Poster Award
Dr. Meghan Rice, PhD, Postdoctoral Fellow in Stoyanova Lab received Best Poster Award at the Canary Foundation Early Detection Symposium for her poster titled: "Role of Notch1 in Early Stratification of Aggressive Prostate Cancer".
Congratulations Dr. Rice!
June 2017
Austin You Su, Undergraduate Student in the Stoyanova Lab receives Stanford Bio-X Undergraduate Research Fellowship for Summer 2017
Introducing undergraduates to the excitement of interdisciplinary research at the frontiers of knowledge is essential for training a new generation to participate in discovery. The Bio-X Undergraduate Summer Research Program (Bio-X USRP) provides an opportunity for these undergraduate students to conduct hands-on research, build awareness of interdisciplinary areas, and network with Bio-X faculty. This formative experience influences their subsequent graduate work at Stanford and beyond.
Congratulations Austin!
November 2016
Dr. Meghan Rice, PhD, Postdoctoral Fellow in Stoyanova Lab received the Helena Anna Henzl-Gabor Young Women in Science Postdoctoral Travel Grant Award.to present her work on "Therapeutic Inhibition of Notch1 in Metastatic Prostate Cancer" at the 2017 American Association of Cancer Research in Washington, D.C.
The Stoyanova lab has discovered that Notch1 is overexpressed in high grade prostate cancer compared to low grade prostate cancer or benign prostate, and that Notch1 synergizes with several common prostate cancer alterations to drive aggressive disease. Dr. Rice determined that Notch1 is a therapeutically relevant target in prostate cancer and is exploring novel inhibition strategies in prostate cancer.
Congratulations Dr. Rice!
September 27, 2016
Dr. Tanya Stoyanova, an Assistant Professor in the Canary Center at Stanford for Early Cancer Detection, was awarded a 2016 Stanford McCormick-Gabilan Faculty Award.
The McCormick Funds were established to support the advancement of women in medicine and/or medical research directly, or by supporting the mentoring, training and encouragement of women pursuing the study of medicine, in teaching medicine, and engaging in medical research.
Congratulations Dr. Stoyanova!
August 2016
Dr. Tanya Stoyanova PhD, Dr. Utkan Demirci PhD, Dr. Sharon Pitteri PhD, and Dr. James Brooks MD, awarded 2016 Canary Seed Grant for their title:
"Investigating the Utility of Exosomes for Prostate Cancer Early Detection"
August 2016